2019
DOI: 10.2147/dddt.s229031
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: PurposeTo evaluate the efficacy and safety of combined 25-gauge (G) pars plana vitrectomy (PPV) with intravitreal dexamethasone implant (DXI) for the treatment of advanced stage epiretinal membrane (ERM).MethodsForty consecutive pseudophakic eyes with idiopathic stage 3–4 ERM and intraretinal cysts were randomly assigned to two treatment groups. Twenty eyes underwent combined 25-G PPV, ERM peeling and slow-release DXI (DEX group), whereas 20 eyes underwent standard 25-G PPV with ERM peeling only (control group… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
25
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 10 publications
(26 citation statements)
references
References 23 publications
1
25
0
Order By: Relevance
“…Iovino et al, reported favorable anatomical and functional outcomes of the Dex implant as adjuvant to PPV in advanced stage ERMs with CME [150]. In this study, both visual recovery and reduction in macular thickness were higher in the Ozurdex-treated cohort up to 6 months after surgery, if compared to the non-Ozurdex treated control group.…”
Section: Evidence Of the Efficacy Of Dex In Vitreoretinal Surgerysupporting
confidence: 48%
See 1 more Smart Citation
“…Iovino et al, reported favorable anatomical and functional outcomes of the Dex implant as adjuvant to PPV in advanced stage ERMs with CME [150]. In this study, both visual recovery and reduction in macular thickness were higher in the Ozurdex-treated cohort up to 6 months after surgery, if compared to the non-Ozurdex treated control group.…”
Section: Evidence Of the Efficacy Of Dex In Vitreoretinal Surgerysupporting
confidence: 48%
“…This aspect may represent an advantage of Ozurdex over anti-VEGF agents, whose half-life is significantly reduced in a vitrectomized eye. Different reports have explored the safety and efficacy of Ozurdex as adjuvant to PPV in distinct retinal pathologies with a special focus on DR, rhegmatogenous and tractional retinal detachment (RD) and epiretinal membrane (ERM) [149][150][151][152][153][154].…”
Section: Evidence Of the Efficacy Of Dex In Vitreoretinal Surgerymentioning
confidence: 99%
“…Two studies presented a randomized design ( Guidi et al, 2018 ; Iovino et al, 2019 ); of the two non-randomized studies, one was prospective ( Sane et al, 2020 ) and one was retrospective ( Savastano et al, 2020 ). All studies except one had a follow-up of 6 months ( Guidi et al, 2018 ; Iovino et al, 2019 ; Sane et al, 2020 ); the report from Savastano and co-workers featured a 3-months follow-up ( Savastano et al, 2020 ). All studies based ERM diagnosis on sd-OCT. A CMT greater than 250 and 300 µm was considered for eligibility by Guidi et al (2018) and Sane et al (2020) , respectively.…”
Section: Resultsmentioning
confidence: 99%
“…Several authors have already described an intraoperative use of the intravitreal dexamethasone implant in patients undergoing vitrectomy for ERM ( Guidi et al, 2018 ; Iovino et al, 2019 ; Sane et al, 2020 ; Savastano et al, 2020 ). However, the outcomes of ERM vitrectomy combined with intravitreal dexamethasone implant appear still controversial ( Guidi et al, 2018 ; Iovino et al, 2019 ; Sane et al, 2020 ; Savastano et al, 2020 ).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation